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List of abbreviations 
 
ACSS Administração Central do Sistema de Saúde 
CEGRD Commission Expert Group on Rare Diseases  
CHAFEA Consumers, Health and Food Executive Agency  
CRP Constituição da República Portuguesa 
ECJ European Court of Justice 
EC European Commission 
DG SANCO Directorate General for Health and Consumers  
DG SANTE Directorate General for Health  
ECDC European Centre for Disease Prevention and Control 
EEA European Economic Area 
eHDSI eHealth Digital Service Infrastructure 
EU European Union 
EUnetHTA European Network for Health Technology Assessment 
eP ePrescription  
ERDF European Regional Development Fund  
ERN European Reference Networks 
GDP Gross Domestic Product 
HiAP Health in all policies approach 
HTA Health Technology Assessment 
IRDiRC International Rare Diseases Research Consortium  
Joint Research Council (JRC 
MeSH Medical Subject Headings 
MS Member States 
NCP National Contact Point 
OECD Organization for Economic Cooperation and Development 
PRISMA-P Preferred Reporting Items for Systematic Review and Meta-Analysis 
Protocols 
PS Patient Summary 
POP Planned and Ongoing Projects  
RCAAP Repositórios Científicos de Acesso Aberto de Portugal 
SNS Serviço Nacional de Saúde 
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SWOT Strengths, Weaknesses, Opportunities and Threats Analysis 
TFEU Treaty on the functioning of the European Union 
WHO World Health Organization 
  
A SYSTEMATIC REVIEW ON THE EUROPEAN LEGISLATION AND POLICY OF CROSS- BORDER HEALTH 





Background and Objectives: The legal basis of cross border health services in 
Europe is based on the Subsidiarity principle, which does not allow further 
integration of health or harmonization between Member States’ health systems. 
Even though there are instruments that address legal issues, governments 
remain responsible for health in their territory.  The purpose of this systematic 
review is to identify and analyze the barriers and clarify facilitators of cross border 
collaboration and care in the European legal framework. To date, the evidence 
on strengths and weaknesses shows the difficulty to overcome legal and 
organizational barriers. However prior authorization of care abroad is against the 
European Union’s free movement and internal market principles, it is justified by 
the need for treatment and can be compensated through a reimbursement.  
 
Data Sources: A systematic review was built through an electronic search on 
PubMed, Web of Science, Scopus, Google Scholar, and grey literature.  
 
Study Eligibility Criteria and Methods: The aim was to include all legible articles 
in the English language, which connect legislation to barriers or facilitators, from 
2009 to 2019. Two hundred and eighty (n=280) records were screened through 
the titles and abstracts and a final list of 21 papers was selected for the review. 
Primary data was the content of 9 studies and 12 studies used secondary data. 
Barriers and facilitators are linked and the second is a possible solution to the 
first.  
 
Results: The eight most influential barriers are connected to eHealth 
interoperability; member states' resistance to cooperate and exchange 
information; legal barrier and countries' political agenda; data protection 
legislation and liability and the economic barrier.  The eight influential facilitators 
are related to possible solutions to the barriers, such as eHealth as a single 
market for healthcare; tools of Health Technology Assessment (HTA); European 
Public Health Program, and funded projects and research.  
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Conclusions and implications of key findings: This review allows a legal and 
graphical analysis of the existing tools that can facilitate and improve cross 
borders health services. Evidence shows that the collaboration and receptivity of 
Member States can lead to better technology assessment, quality and common 
standards in health, liability, and a friendly single market for patients, that could 
give efficient answers in critical situations.  
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This systematic review presents an analysis of cross-border health care in the 
European Union (EU). Although a Directive was implemented in the European 
community to suppress the barriers related to access to healthcare, there are still 
obstacles that should be analyzed. The literature identifies different barriers, 
some are financial, other linguistic, cultural, informational, or geographical, and 
those will be identified through this study. 
As the world becomes more globalized and interconnected, there is a need to 
approach the health sector and to understand what can make it balanced, 
sustainable, and accessible to everyone. How can it be prepared for the new 
challenges and crises, like the one we live nowadays, with the COVID- 19 
pandemic.  
Cross-border care and collaboration may bring the potential for learning and 
expertise for and from the different European systems, although the process is 
complex when it comes to negotiating between such different health systems, 
particularly when there are socio-economic, political, cultural, or legal factors 
involved. 
This study will bring new insights and lights about patient’s rights, mechanisms, 
processes, and legal tools of cross-border care in the European Union and 
Portugal. The aim is to understand the barriers and facilitators of this type of care 
from different perspectives, not only from European Union lenses. The framework 
proposed is a systematic review that extracted legal and political facilitators and 
barriers for the actors involved in this field of health. 
Although there were initiatives on the health field before, the Maastricht treaty 
from 1993 and its later amendments marked the legal basis in the field of public 
health, which was strengthened by the European Court of Justice (ECJ) or the 
so-called Kohll and Decker rulings about receiving care abroad in 1998. Later, 
the Lisbon Treaty on the Functioning of the European Union (TFEU) and its 
Article 168  recognized and embodied the European Union (EU) with limited 
legislative powers on health matters. (Russell, 2014) (Rosenkötter et al., 
2013)(European Union, 2008) According to the Treaty: 
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“Union action, which shall complement national policies, shall be directed towards 
improving public health, preventing physical and mental illness and diseases, and 
obviating sources of danger to physical and mental health. Such action shall 
cover the fight against the major health scourges, by promoting research into their 
causes, their transmission, and their prevention, as well as health information and 
education, and monitoring, early warning of and combating serious cross-border 
threats to health.” (Article 168 TFEU) 
 
The understanding of the European cross- border health care framework is 
important, because of efforts put in the development of an efficient framework 
show low significant improvements in the levels of patient mobility, patients’ 
informed choices about their rights, and cooperation on bureaucratic procedures 
across Europe (e.g.: national systems of reimbursement, charging of incoming 
patients).  
A Report for the European Parliament from 2019 indicates that the levels of 
patient mobility are low. The 2015 Eurobarometer showed that fewer than 20% 
of citizens were informed about their patient’s rights, especially in the information 
about the treatments and reimbursement procedures. (Parliament, 
2019)(European Court of Auditors, 2018) The respondents who received cross- 
border care were 5%, although 49% reported that they would be willing to travel 
to another EU country for this purpose. (Brekke et al., 2016) For patients with 
rare diseases and who live in geographical proximity to other countries, cross-
border care is the most appropriate and accessible treatment method. 
(Parliament, 2019)  
Adding to that, approximately 5800 rare diseases affect 6-8% of all European 
citizens. Knowledge is scarce on this front, but 24 European Reference Networks 
(ERN’s), specialized in rare diseases, started working in 2017. These cooperate 
with 900 highly specialized healthcare units from more than 300 hospitals in the 
EU, EEA countries,1 and Norway. (Parliament, 2019) Breakthroughs are needed 
in the front of investigation, especially in what concerns using an adequate 
approach to reach different levels of understanding, such as patients, providers 
of care, and policymakers.  
 
1 All the EU countries, including Iceland, Liechtenstein and Norway. 
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To date, the European legal framework on cross border healthcare rights is set 
by the Directive 2011/24/EU in parallel to Regulation 883/2004 (or Portable 
Document S2) on the coordination of social security systems. (Parliament, 2019) 
The Directive applies without prejudice to the Regulation and the second is more 
favorably used for planned and unplanned care. Under the Regulation, for 
unplanned care, there is not a need for up-front reimbursement claims. While the 
Directive only covers the cost equivalent to the treatment in the home country, 
the Regulation covers full costs, the rate of reimbursement is the one applied in 
the treatment country. (Parliament, 2019)(Wilson et al., 2018)  
However, the Directive and Regulation are not the only ways by which care is 
provided outside of home countries. “Several Member States have adopted bi-
lateral and multi-lateral parallel procedures to address the needs of care in their 
countries.”(Wilson et al., 2018)(Van der Molen & Commers, 2013) 
In 2018, 23 Member States had implemented a system of prior authorization and 
reported their data. It was proved that the number of prior authorizations under 
the Directive in that year was low (7379 cases), yet it was higher than the year 
before (5902 cases). (Wilson et al., 2018) Data proves that patient mobility cases 
under the Directive are growing for the ones which require prior authorization or 
not. In that year, there were 232 054 cases of cross border care, compared to 
205 417 treatments in 2017.  
The spending on reimbursements also rose in 2018, when compared to 2017, 
from 49,9 M€ to 73,2 M€. The requests for information from cross- border 
healthcare, through the NCP’s rose significantly, from 69 723 to 95 565.  (Wilson 
et al., 2018) 
Where prior authorization was required, 70% of the patient mobility under the 
Directive is distributed in five groups of countries: the French are the ones that 
most seek cross-border care, traveling to Germany, Spain, and Belgium. The 
Irish seek treatment in the UK and vice-versa. Also, citizens from Luxembourg 
usually travel to Germany and Slovakia to the Czech Republic. 
 
Figure: Flow of all patient mobility with Prior Authorization in 2018 under the 
Directive 
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Source: European Commission- Health and Food Safety 
 
As well in the next graph, when authorization is not required, France dominates 
the picture, representing 63% of all patient mobility. Following France, the biggest 
flow is from Denmark to Germany, Poland to the Czech Republic, showing the 
pattern of neighboring Member States. 
Figure: Flow of all patient mobility not requiring Prior Authorization in 2018 under 
the Directive 
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Source: European Commission- Health and Food Safety 
The most common patient mobility is between neighbor states, as can be 
observed in the next graphs. (European Union, 2019)(Wilson et al., 2018) Of all 
the European territory, 40 % is a cross- border region, which leads to easier 
cooperation. (Parliament, 2019)  
A reason that justifies his phenomenon is that there are cultural links and shared 
borders that facilitate the provision of health care, although some exceptions, 
such as patients traveling for care from Norway to Spain. (Legido-Quigley et al., 
2011) 
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The next graph from the World Health Organization, lastly updated in October 
2019, shows the total health expenditure as a percentage of GDP in the World. It 
classifies countries and sub-regional averages for the WHO European Region; 
Members of the European Union; Members of the EU before May 2004 (EU15); 
Members of the EU after May 2004 (EU13); Commonwealth of Independent 
States; Central Asian Republics Information Network members (CARINFONET); 
South-eastern Europe Health Network members (SEEHN); Nordic countries and 
Small countries. Nordic countries and Switzerland are the ones that spend more 
money on their health systems. 
The European public health agenda spends around 10% of the GDP in the 
European Union’s economy and there are estimates which point out for an 
increase to 12,6 % in 2060. In 2016, 19,2% of the EU population aged over 65 
years old and this number is expected to rise. Because of this aging population, 
the Council of the EU emphasized the need to create a supportive framework for 
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Socio-economic and political considerations emerge on both, the European and 
Member States sides. Although healthcare is national competence (Article 168 of 
TFEU), the Directive 2011/24/EU sets the right to travel to another EU country to 
receive care. This Directive aims to facilitate access to safe and high-quality 
cross-border healthcare, based on the free choice of EU citizens. In some 
situations, this is the most accessible and appropriate care for patients, especially 
if treatment is not available in their home country. Yet, the Directive does not 
encourage patients to be treated abroad. (European Union, 2019) 
On the other side, the Member States’ position is based on the Subsidiarity 
principle and they do not want to spend their resources abroad, because sending 
patients abroad implies the outflow of public funding. This can also be motivated 
by the confusion in the Directive’s implementation process, which may rise socio-
economic differences between countries in matters such as prior authorization, 
costs, reimbursement, and treatment. (Azzopardi-Muscat et al., 2018)(Vasev, 
2017) (Dimitrios, 2016)(Exter et al., 2015)(Legido-Quigley et al., 2012) 
Contrary to the vision that there is an outflow of national funding, in some cases 
the exit of patients can also benefit the Government and its payers. In addressing 
problems of the national health care system, such as capacity, costs, waiting lists, 
expensive facilities or treatment, and efficiency- especially significant in small 
countries. (Laugesen & Vargas-Bustamante, 2010) 
Cross- border healthcare is funded by the second (2008-2013) and third (2014-
2020) Health Programmes, which totalize 64 million euros per year. The 
Programme supports joint actions and annual plans for the Member States, 
cooperation projects, the functioning of NGO’s and cooperation with international 
organizations.  
The Research Framework Programme (Horizon 2020 for 2014-2020), the 
Connecting Europe Facility, and the Structural Funds are also funding 
instruments. (European Court of Auditors, 2018) The Commission supports 
cross- border cooperation through studies and actions, such as Interreg, funded 
by European Structural and Investments Funds. (European Union, 2019) 
The transposition of the Directive highlighted some political and governmental 
barriers. Although the deadline was on 25 October 2013, 26 countries received 
infringing procedures for late or incomplete implementation. Only until late 2016 
was the process complete, with Iceland’s transposition. Somehow, Member 
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States were not interested in the negotiations, especially judicial decisions on this 
matter. (Parliament, 2019)(Wilson et al., 2018)(Azzopardi-Muscat et al., 
2018)(Hatzopoulos & Hervey, 2013) 
During the past 10 years, evidence on cross- border healthcare was common 
with the implementation of the Directive 2011/24/EU and further processes. 
These studies aimed to understand the legal framework barriers, processes to 
receive care abroad and how was the directive transposed in different countries. 
Most of the research focus is on eHealth interoperability and legal challenges 
between health systems, especially liability and data protection. (Van der Molen 
& Commers, 2013)(Russell, 2014)  
This systematic review seeks to understand and systematize the current 
knowledge about barriers and facilitators of cross- border care.  
The European Commission identified four potential barriers for the low number of 
patients traveling for care, which were: the national systems of reimbursement, 
prior authorizations, charging of incoming patients, and other administrative 
requirements. Other issues or solvable challenges are related to the continuity of 
care, the exchange of information between health professionals, and 
organizational and administrative barriers. These barriers can affect cross-border 
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European Cross- Border Framework 
 
Overview of Directive 2011/24/EU 
 
Within the Commission, the Directorate General for Health (DG SANTE) is the 
first to manage the implementation of the Directive 2011/24/EU, namely the 
strategic planning, monitoring, and evaluation of the Health Programme. This 
Directorate supports the Member States in the developments of National Contact 
Points (NCPs), European Reference Networks (ERNs), and assists the 
recognition of prescriptions.  
This work is done in an international and cooperation environment, which 
includes other DGs (Directorate-General for Research and Development-DG 
RTD; Directorate-General for Communications networks, content and 
technology- DG CNECT2), EU agencies, such as the Consumers, Health and 
Food Executive Agency (CHAFEA) and the Joint Research Council (JRC3). 
(European Court of Auditors, 2018) 
 
The main objectives of the directive were systematized: 
- Sets out Member States’ patient’s rights to access and information by the 
National Contact Points (NCPs) about the high- quality health care and 
rights for reimbursement; 
- Seeks to facilitate eHealth cooperation between countries through data 
exchanges and ePrescriptions; 
- Give access to healthcare for rare diseases, through European Reference 
Networks (ERNs); 
- Cooperation on Health Technology Assessment (HTA), exchanging 
reliable information and expertise; 
 
The Cross- border Healthcare Directive describes the priority areas, which not 
only set the rights of EU citizens who seek planed care abroad but also seek to 
facilitate cooperation between the Member States. eHealth and cooperation on 
 
2 DG CNECT manages eHealth. 
 
3 JRC is cooperating with DG SANTE in maintaining the European platform on rare diseases. 
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rare diseases are examples of this “teamwork”.(European Court of Auditors, 
2018) 
Directive 2011/24/EU clarifies the jurisprudence of the Court of Justice of the 
European Union concerning reimbursement of patient’s cost when receiving care 
across borders (Article 7) and the prior authorizations needed (Article 8). Besides 
this, the Directive codifies instruments that can be of help to patients using this 
method of treatment. (Wilson et al., 2018)(Lorenzetti, 2018)  
A whole framework is set through the Directive and the responsibilities of Member 
States concerning cross-border health care are explicit in Chapter II. Article 4 
clarifies that “the principles of universality, access to good quality care, equity and 
solidarity” should be under the legislation of all the Member States. (Lorenzetti, 
2018)  
Each Member State shall designate one or more national contact points to 
facilitate communication and information between patient organizations, 
healthcare providers, and insurers. (Article 6).  
Also, with the support of the European Commission, Member States are intended 
to develop European reference networks (ERNs) or collaborative reference 
networks between health providers and centers of expertise, in particular in the 
area of rare diseases- Article 12. (Lorenzetti, 2018) 
 
European Reference Networks (ERNs) 
ERNs are a part of the European strategies and policies for rare diseases. It was 
endorsed by Council’s Recommendation on action in this field, on the 8th of June 
2009. The ERNs support Member States' national rare disease plans, contribute 
to the standardization of rare diseases nomenclature, and develop research. 
(European Union, 2019) 
ERNs objective is to reduce the time of diagnosis, improve access to care for rare 
diseases, and offer platforms for the development of guidelines and exchange of 
expertise. 24 ERNs were launched in 2017, for different rare diseases. They are 
funded by the EU Health Program, which also helps in the development of IT 
tools and patient registries.  
In November 2017, a web-based application (Clinical Patient Management 
System or CPMS) was provided by the Commission, to create a virtual panel with 
medical experts, which aim was to share information on specific cases. Data and 
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images, if consented by patients, are shared to get a high- quality diagnosis and 
treatment. In 2018, there were 952 healthcare providers (hospital units and 
institutes) across the EU.  (European Union, 2019)  
 
Box 1- Up to date information on European Reference Networks from the 
2019 Report of the European Court of Auditors 
The challenges of ERNs are related to the fact that the Commission has not 
updated its rare disease strategy singe 2008, even though it is working on 
initiatives such as Networks and the EU-wide platform for rare disease 
registries. Also, the Commission did not apply all the lessons learned from the 
European Reference Networks pilots, which were evaluated by the 
Commission’s consultative committee on rare diseases (EUCERD). 
There are issues to be addressed:  
 
• sustainability of the Networks beyond their initial funding period;  
• the development of continuous monitoring and quality control system for 
the Network members;  
• the administrative challenges and financial costs of expanding a 
Network and  
• sustainable support for patient registries  
Currently, the Commission and the Board of Member States for the Networks 
are trying to address these points. There is some progress in monitoring quality 
through indicators from the ERNs. However, the integration of Networks into 
national health systems has been difficult and issues have emerged- 
challenges in the fields of collaboration with industries, continuous monitoring, 
collaboration with industry, data policy and registries, management, integration 
intro Member States healthcare systems, and, sustainable funding. 
The 24 ERNs do not have an effective system to assess participants through 
any specific criteria. Although, in the beginning, the applications to join the 
ERNs were evaluated by the Commission. To support the ERNs, the 
Commission provided funding from different spending programs (Health 
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Program, Connecting Europe Facility), as the EU budget does not contain a 
specific budget line for this purpose. 
Each ERN receives 1 million euros for administrative costs, over five years. 
The Commission also provides grants to support ERNs in achievements and 
objectives. However, in 2018, twenty ERNS responded to a Commission’s 
survey and indicated that the sustainability of financing is a big challenge.  
An EU-wide platform for rare disease registries is a database that enables 
epidemiological and clinical research on rare diseases. It was created by DG 
Joint Research Center (JRC) and aims to promote EU-level standards for data 
collection and provide interoperability tools for the exchange of data on rare 
diseases. It leads to the fragmented data contained in rare disease patient 
registries across Europe. To accomplish the aim of standardization, the 
Commission funded RD- Connect project, which objective was to create a 
directory of patient registries for rare disease research. JRC platform was due 
to go live in February 2019. 
 
There are highly specialized healthcare units taking part in ERNs, located in 25 
EU Member States (plus Norway). The distribution of the healthcare providers 
varies and no ERN covers more than 19 Member States. Italy has the highest 
number of healthcare providers participating in ERNs, because of its recognized 
and long national strategy on this field of rare diseases, as shown in the next 
figure.  (European Union, 2019) 
 
Graph 1.- The distribution of 952 healthcare providers (hospital units and 
institutes) across the EU 
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Source: Report from the European Court of Auditors 
 
Directive Transposition and Cross- Border Care Across the Member States 
Directive 2011/24/EU implementation in the Member States shall be supported 
by the Commission, its representative, and a Committee (Article 16), consisting 
of representatives of the MS’s. (Lorenzetti, 2018) Besides this, the Commission 
has to guide the National Contact Points, which is accountable for the provision 
of information to patients on cross- border treatments.  
More than half of the NCPs did not explain the difference between receiving care 
under the Directive or the regulation. For this reason, in 2018, the Commission 
asked to address this confusion and make the information accessible to patients, 
through a practical toolbox. Yet, further work is needed to overcome this barrier. 
Another development needed is to include in all the NCPs information about the 
European Reference Networks, liaising with the ERN Board of Member States 
for ERNs. (European Union, 2019) 
Although the Directive’s transposition deadline was on 25 October 2013, the 
Commission opened 26 infringement procedures for late or incomplete 
notification of the transposition on recognition of medical prescriptions. Later, 
when the Member States have provided complete notifications, in 2017, those 
procedures were closed. (European Union, 2019)  
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The transposition was monitored by a check on National legislation of the 
Member states, which aim was to establish whether they have correctly 
transposed the Directive. For this, some 4 barriers or strategic areas were 
identified: reimbursement systems, prior authorization, administrative 
requirements, and the charging of incoming patients. A Report from the European 
Court of Auditors refers that the Commission checks worked as facilitators and 
led to improvements. (European Union, 2019) 
As the majority of Member States were late in the adoption of the Directive to 
national legislation, this can explain the late provision of data to the Commission 
and slow development in the delivery of cross border treatments. In 2017, 26 
Member States provided data, and 6 of them were incomplete. Also, that data 
was not comparable between States, because the reported information on 
reimbursement was not specific if under the Directive or the Regulation. 
 
eHealth towards Sustainable Systems in Europe 
eHealth is part of the European Commission’s strategies to form a Digital Single 
Market and Commission’s Action Plans on health. As explicit in the article 14 of 
the Directive 2011/24/EU, eHealth’s purpose is to reach socio-economic benefits 
to European Health systems through services and interoperable exchanges. 
Also, to secure data protection, trust and improve continuity and quality of care 
to all citizens of the Member States, which transposed the Directive. (Parliament, 
2019)(Lorenzetti, 2018)  
A voluntary network of Member States’ authorities is established under article 14 
of the Directive (eHealth Network). This network supports the development of 
common standards for transferring data. It links competent authorities dealing 
with digital health. The Joint Action (eHAction) provides all the scientific and 
technical support to the eHealth Network. (Duclos, 2020)(European Union, 2019) 
The article 11 of the Directive describes another important instrument, the 
recognition of prescriptions issued in another Member State. According to the 
European Commission, ePrescriptios allows Member States’ citizens to receive 
medication in a pharmacy different than the one that prescribed it. It is an 
electronic exchange.  
If a medical product is prescribed in another Member State, the State must ensure 
that the medication will be dispensed in the patient’s State territory, according to 
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national legislation in force, except justifiable cases (e.g.: authenticity, what is 
necessary, and patient safeguarding). (Lorenzetti, 2018) 
For this purpose, it is necessary to draw up guidelines that may be shared 
between health professionals. This is referring to a non- exhaustive list of data 
that are to be included in patients’ summaries to enable continuity of care and 
safety.  
According to the European Commission, Patient summaries provide basic 
information about patient’s health, for example, their allergies, surgeries, current 
medication, etc. They collect the essential information translated into the doctor’s 
language, if there may be a linguistic barrier. 
The patient summaries are part of a larger collection of data, the Health Record, 
which gathers all the health information of a specific patient. Both practices are 
open to all Member States. It is expected that by 2021, these services will be 
implemented in 22 EU countries. 
The interoperability would also reflect on effective methods for enabling the use 
of medical information for public health and research. This transfer of data 
between the Member States would be supported by the European Union, in due 
observance of the principles of data protection set out in Directives 95/46/EC and 
2002/58/EC.(Lorenzetti, 2018) 
The Recommendation on Electronic Health records sets a framework that will 
enable citizens to access and exchange their health data across borders. The 
work on this exchange of health data is carried out under e-Health Digital Service 
Infrastructure (eHDSI) by the Member States and the European Commission and 
is implemented through the Connecting Europe Facility Programme (CEF)4. The 
eHDSI connects eHealth national contact points to exchange two sets of data: 
patient summaries and ePrescriptios. The first exchange took place between 
Estonia and Finland in January 2019, but 22 MS are expected to exchange such 
information by 2021. (Gabriel, 2019) 
The midterm evaluation for the Programme’s eHealth action plan 2012- 2020 
showed that eHealth is facing barriers related to its adoption and its complexity, 
governance, local conditions, and stakeholder engagement. There is difficulty in 
 
4 The Connecting Europe Facility (CEF) in Telecom is an instrument to facilitate cross-border interaction 
between public administrations, businesses and citizens. Digital service infrastructures and broadband 
networks are developed in order to create interoperable digital services that sustain the Digital Single 
Market strategy. 
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ensuring the commitment of clinicians, IT staff, and managers. (European Court 
of Auditors, 2018) 
 
Box 2- Up to date information on eHealth from the 2019 Report of the 
European Court of Auditors 
The Commission and MSs are building an EU- wide voluntary eHealth Digital 
Service Infrastructure (eHDSI) to help the exchange of data on ePrescriptions 
and Patient Summaries. The eHDSI includes 22 Member States and seeks to 
connect European eHealth systems through a “portal”- National Contact Point 
for eHealth (NCPeH). (European Union, 2019) 
Exchanging patients’ data requires a whole governance framework, supported 
by the Member States, but the 2018 eHealth Strategy did not include an 
implementation plan. The current Action Plan runs from 2012 until 2020, in 
which eHealth strategy includes the exchange of electronic health records. Yet, 
only the 2018 eHealth strategy mentions challenges that need to be addressed, 
such as the introductions of the General Data Protection Regulation and 
cybersecurity threats.  
The 2019 Report from the European Court of Auditors addresses the difficulties 
of the Commission in deploying EU- wide eHealth Infrastructure. The work on 
exchanges of patient health data was divided into steps. First, a pilot project 
(epSOS) was developed between 2008 and 2012, with 18 million euros of 
funding.  
epSOS was meant to create an Information and Communication Technology 
framework to allow a secure exchange of patient data. It developed the content 
of Patient Summaries and ePrescriptions, mechanisms for testing and 
assessing the intended exchange of information. EpSOS also contributed to 
the development of eHealth guidelines, common standards, and other 
interoperability specifications, which demonstrated the Member States' 
commitment to cooperate.  
Despite this, the test provided limited practical evidence, because it consisted 
of only 43 transfers of patient data, a statistically not relevant number. More 
evidence was needed, but the approach per se was considered valid by the 
European Commission. The E.C. considered interoperability problems at legal, 
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organizational, and semantic levels to be bigger challenges. These were the 
first steps to the development of the large scale EU- wide eHealth Infrastructure 
(eHDSI). (European Union, 2019)  
In 2015 was launched a deployment project, the EU- wide eHealth 
Infrastructure, costing 35 million euros to the Commission. Its technical, legal 
and semantical specifications are based on the epSOS project. eHDSI’s 
greatest challenges are related to the high volume of patients and providers 
(hospitals and pharmacies) which will use eHealth services. 
In 2019, the European Commission stated that cross- border health data 
exchange will start to be an accepted practice between the Member States. 
Although the Member States reported having the capacity to establish eHealth 
portals on their territory, a confirmation of their readiness to start using this 
instrument did not come. At that time, Finland was ready to send ePrescriptios 
and Estonia to receive them. According to the Commission, Czechia and 
Luxembourg could receive Electronic Patient Summaries, but no Member 
States was able to send them via eHDSI.  
 
According to the European Commission, in 2020, doctors from Croatia can 
access health data of citizens coming from the Czech Republic, Malta, and 
Portugal. Luxembourg can access health data from the Czech Republic and 
Malta. Malta can access health data coming from Portugal and, vice-versa, 
Portugal can access health data of citizens coming from Malta. 
Health data of citizens from the Czech Republic can be consulted by doctors from 
Luxembourg and Croatia. Malta’s health data can be consulted by Luxembourg, 
Portugal, and Croatia. Portugal’s health data can be accessed by Malta, Croatia, 
and Luxembourg. 
ePrescriptions of citizens from Croatia and Estonia can be already retrieved in 
pharmacies in Finland. Those from Finland and Portugal can be recognized in 
Estonia and Finland’s ePrescriptions can also be retrieved in Croatia. 
Pharmacists of Croatia can dispense ePrescriptions of citizens from Finland. 
Estonia can dispense ePrescriptions for Finland, Croatia, and Portugal. Finally, 
Finland can dispense ePrescriptions of citizens from Estonia. 
With the coronavirus pandemic, interoperability guidelines for approved contact 
tracing apps in the EU were adopted by the Member States through the eHealth 
A SYSTEMATIC REVIEW ON THE EUROPEAN LEGISLATION AND POLICY OF CROSS- BORDER HEALTH 
CARE: BARRIERS AND FACILITATORS 
 
 26 
Network. This is the first follow-up action developed by the Union’s toolbox, which 
aim is to support contact tracing cross-border infection chains and will be 
deactivated at the end of the pandemic. The app is voluntarily installed by citizens 
and based on Bluetooth proximity technology that does not allow the tracking of 
people’s locations, safeguarding patient’s privacy.  
They alert people who have been in proximity to an infected person for a certain 
duration, intending to isolate and test them. For example, if a person gets a 
positive diagnosis for COVID-19, the public authority will allow him or her to 
confirm that through the app. After this, the electronic contact which traced the 
people with whom there was contact, proceed to warn them. This also happens 
in the reverse, if a contact of yours is tested positive, there will be a notification 
to protect yourself and the people around you. This is a way to break the 
transmission chains. (e-News 13/05/2020, 2020)(Commission, 2020) 
 
Cooperation on Health Technology Assessment 
Cooperation on health technology assessment (Article 15 of the Directive) is the 
exchange of scientific information among the Member States within a network 
which includes national authorities and bodies responsible for health technology 
assessment (M.S. communicate names and contacts to the Commission).  
This joint work is based on good governance, transparency, objectivity, and 
independence of expertise. The network gives support to cooperation between 
the Member States, helps with reliable information on relative efficacy as well as 
on the short and long-term effectiveness, avoiding duplication of assessment. 
(Lorenzetti, 2018) 
This network is receiving technical, financial, and administrative support from the 
Union, with measures taken by the European Commission. The transferable 
scientific information and shared methodologies can be used in national reporting 
and case studies, which bring innovation to research. 
 
Healthcare that May be Subject to Prior Authorization and Reimbursement 
The Member State of affiliation shall guarantee the authorization when the 
conditions laid down in Regulation (EC) No 883/2004 have been met. In the case 
of a rare disease, a clinical evaluation can be carried out by experts. Also, if 
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healthcare is not provided within a time limit, due to waiting lists, for example, the 
authorization must be guaranteed.  
The reimbursement is set at the home country cost of the same treatment. Yet, 
requirements for upfront payment for costs, although approached in the Directive, 
is still a challenge to face. (European Union, 2019) 
Healthcare that may be subject to prior authorization shall be limited to healthcare 
which ensures sufficient and permanent access to a “balanced range of high-
quality treatment” or to control costs and avoid waste of financial, technical, and 
human resources. The prior authorization is also limited to healthcare which 
involves overnight hospital accommodation or requires the use of highly 
specialized and cost-intensive medical infrastructure or equipment. It is also used 
when involves treatments presenting a risk for the patient or population or quality 
and safety are not assured by the providers. (Article 8)(Lorenzetti, 2018) 
Only 0,05% of EU citizens (200 000 requirements a year) have received planned 
medical treatment abroad under the Directive. For the unplanned care, under the 
Regulation, 2 million claims a year were registered. (European Union, 2019) 
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Portuguese Cross- Border Framework 
 
Portuguese Public Health Background and Principles 
The Portuguese health system or Serviço Nacional de Saúde (SNS) was possible 
and created with the country’s democratization. Although the system was 
planned to be founded in 1976, only in 1979 it entered into functioning, under the 
national Law No. 56/79, which was revoked by another important one, which 
stated the health bases in Portugal- Lei de Bases da Saúde (LBN) through Law 
nr. 48/90 from 24th of August, revoked later, by the Decree-law no. 11/93 from 
the 15th of January. (Sousa, 2014) 
SNS implementation was made in parallel to other European health systems and 
followed the Beverage model, in comparison to other European countries, which 
adopted the Bismarckian model of healthcare systems. Contrary to the other 
states, the Portuguese system was marked by social instability, which difficulted 
all the implementation process. (Sousa, 2014) 
Studies on the legislative health frameworks usually seek to describe and analyze 
the existing rules and laws, which are significant to the different institutions and 
health systems. As present in National Constitutional Law from Constituição da 
República Portuguesa (CRP) 1976, health is a fundamental right. Under Article 
64 of the constitution, everybody has the right to protect health and the state has 
duty to preserve it and promote it through a universal, general, and almost free 
health service, which takes into account the economic and social differences 
between citizens. This model tends to be free, fair, and equitable, as it is financed 
by the state. (CRP, 2017) 
The Law No. 48/90, or the law of the legal basis of public health, reflects the 
statute of SNS and is constituted by three main points: the separation of public 
and private sectors, which should develop independently from one another, and 
the concern with alternative health insurance and, finally, growth in private 
financing in the health system and management of public unities.  
The first base of the Law states that the State promotes, facilitates, and ensures 
health access to all citizens. The next basis also highlights the importance of the 
state’s responsibility in health. (Repúblíca, 1990)  
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In 2019, after 40 years of SNS functioning and almost 30 years since the law No. 
48/90 of 24th of August entering into force, it was revoked, through the Assembly 
of the Republic, by Law nr. 95/2019. This law is an integrated part of the previous 
law of health bases and also states about the provision of basic law as a 
mechanism to protect health as a human and fundamental right. (Assembleia da 
República, 2019)  For this purpose, a commission was created to update the 
previous law and create a document which would respect the human dignity 
(Article 1 of CRP), the principle of equality (article 13 of CRP) and highlight the 
protection of the fundamental rights (article 64 of CRP), which is a right related to 
all other universal human rights. At the same time, it was important to also 
contribute to updating the adoption of integrated people-centered health services, 
which would create value for society in the long run. (Roseira, 2019)(Pereira, 
2019) 
New times brought the necessity to approach health from a different perspective, 
represented by the technological, scientific, and worldwide promotion of equity 
and social cohesion. This is a multi-sectorial approach to the fundamental right 
in health, which brings together different sectors of society such as the social 
economy, the private sector of health with the SNS. The aim is to bring 
transparency, effectiveness, and efficiency. (Pereira, 2019) 
 
The Transposition of Directive 24 in Portugal 
In 2014, the Diary of the Assembly of the Republic of Portugal published the 
Proposal of Law No. 206/XII. This proposal and previous rulings gave form to the 
Law No. 52/2014, which mentions that the health services subject to previous 
authorization should be defined and communicated to the Governmental 
representative of health and the European Commission. (de Sousa, 2014) 
Law No. 52 establishes standards to access cross-border healthcare, through a 
previous authorization by the health system and promotes cooperation, 
transposing Directive No. 2011/24 / EU, of the European Parliament and of the 
Council, of 9 March 2011, and the Commission’s Implementing Directive No. 
2012/52 / EU, of 20 December 2012. 
As it is stated in the Article 2 No. 2, the previous law and its norms to access 
cross border healthcare, transposing the Directive 2011/24/EU of the European 
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Parliament and Council, reflects and empowers principles already represented in 
the Regulation 883/2004 concerning the coordination of social security systems. 
In Article 3 definition of “Beneficiary” of this law, is every person who has access 
to the national health system, including all Portuguese citizens, or citizens from 
other countries who have a legal residence in Portugal. 
The right to reimbursement (Article 8) applies to services provided abroad, in 
countries covered by the Directive 2011/24/EU, with the condition that those 
services should be provided and are of the responsibility of the Portuguese state. 
Those are services that should be part of the Portuguese Health system. The 
delivery of services eligible to reimbursement is defined in the table of prices of 
the National Health System or the Regional health systems of Açores and 
Madeira (No. 2 of Article 8). Furthermore, the reimbursement should only cover 
the amount which would be spent at the national level, by the health system. (No. 
5 of Article 8) 
The request for reimbursement can be performed by the beneficiary through the 
submission of a fulfilled document to the user’s portal of ACSS (Portal do Utente), 
the Central Administration of the Health System, or to the competent authority of 
the independent regions of Açores and Madeira.  
Also, the beneficiary can ask for this service to the competent health units near 
their residential areas and its request is subject to authorization. This request 
should be made within 30 days from the payment of care services by the 
beneficiary. All requested personal and documents and proofs of payment to 
present are described in Article 9. The latter reimbursement will be made 
considering the health system’s table of prices. (Article 10 and 14) 
Finally, law 52 states the recognition of medical prescriptions issued in the other 
Member States, if those are following national legislation (Decree-Law No. 
176/2006) and if the prescription is legible in terms of patient identification, 
pharmaceutical form, quantity, and the right dosage. (Article 15)  
Cooperation on this front is extended to an official identification and approval, by 
the Ministry of Health, of national reference centers for the diagnosis and 
treatment of rare diseases. (Article 16) The national authority is also responsible 
for the health technology assessment. The Ministry participates in the European 
network for HTA and helps to standardize and manage those assessments. 
(Article 18) 
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The Portuguese National Health Service site on the internet presents different 
paths and procedures through which citizens can get access to planned cross-
border care. Those situations are rare because they are only for cases when the 
treatment cannot be provided through the Portuguese national health system. 
These are exceptional cases, as Portugal has similar human resources and 
technical conditions as other European countries.  
There are four pathways to receive this type of care: through a request for Medical 
Assistance abroad under national law; by presenting the portable document S2 
(previous form E112, which is still in force); through the request for Prior 
Authorization under Directive 2011/24/EU or the European Health Insurance 
Card. 
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Protocol and Registration 
The collection and analysis of records followed a protocol prepared according to 
the guidelines of PRISMA-P (Preferred Reporting Items for Systematic Review 
and Meta-Analysis Protocols) 2015 checklist (Liberati et al., 2015) and PRISMA 
2009 Checklist, a previous version, which included more items than the first. ( 
Liberati et al, 2009) 
 
Eligibility Criteria 
The systematic review was written between December 2019 and July 2020 as 
part of a Master’s Thesis. The aim was to include all relevant studies found 
through a retrospective analysis of the legislation on cross-border healthcare, its 
barriers, and facilitators, between 2009 and 2019. The research was made in 
English, a European and universal language. The definition of cross-border 
healthcare was the one referred to in the Directive 2011/24/EU of the European 
Parliament and Council. (Lorenzetti, 2018) 
There are different types of facilitators and barriers, which may be focused on the 
patient, partners, or hospitals. Although a general view of all will be presented, 
the focus of this review is on European legislation, as this is what may drive cross 
border collaboration forward in the long run.  
The European legal framework is closely linked to its policies and, consequently, 
to the existing projects, joint actions, and initiatives.  
The tools applied to promote collaboration in cross-border care are part of the 
European legal framework, such as border- region projects, commissions to 
evaluate good practices, and research projects. The European Regional 
Development Fund (ERDF) is an important source for the funding of all the 
projects in the area of cross-border healthcare, especially for interregional 
development (INTERREG). The European Commission plays an important role 
in the development of cross-border tools, such as EU’s Framework Programs for 
Research (Horizon 2020), and Public Health Programs Euregio I and II. (Glinos 
& Baeten, 2015) 
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Information Sources  
The electronic research was made between December 2019 and March 2020 
and was divided into two parts: (1) selection of three Databases and (2) research 
through grey literature. In the first part, search strings were composed to answer 
the study question. ["Delivery of Health Care"[Mesh] AND cross-border AND 
"Europe"[Mesh]] was used in the PubMed database; and ["Health Care" AND 
“cross-border” AND "Europe"] was performed in the Web of Science and Scopus 
databases.  
A 10 years filter was activated to select the most recent published studies. 
Medical Subject Headings (MeSH) vocabulary was explored and used in the 
PubMed research to perform an efficient range of results. 
The research through grey literature was made in the Google Scholar database, 
RCAAP (Repositórios Científicos de Acesso Aberto de Portugal), an online library 
of the European Commission. 
 
Databases Grey Literature 
PubMed 




Library of the European Commission 
 
Search Strategy 
For the first database, the MeSH dictionary (available through the PubMed) was 
used. When searching for “healthcare”, the “Delivery of Health Care” concept, 
which was introduced in 1971, is suggested as a definition of key terms and 
synonyms related terms. Also, Europe integrates the vocabulary thesaurus, 
identified as a continent. It was not used “European Union”, as cross-border 
healthcare directive includes countries that are not member states of the union 
(Norway, Iceland, Great Britain, Liechtenstein). Thus, all European countries 
were included. Both are indexed in the PubMed articles, unlike “cross-border”, 
which was identified as a key expression for all possible fields.  
Along with the search phrase used, the Boolean operator “AND” was used to 
yield abstracts that include all terms. Here, was important to generate the right 
number of articles about cross-border healthcare in Europe, to minimize bias. 
The available “10 years” filter on the website was performed.  
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Once this research process was validated for identifying eligible studies, the 
selected strings were used systematically in the other two databases. The 
narrowness of the search was reasonable and sufficient, as the PubMed 
database identified 116 studies, Web of Science 51, and Scopus 156 articles. 
After that, a study exclusion checklist was used to remove the abstracts that were 
not eligible, rather than using more filters or limiting Boolean operators. 
The search was restricted to the English language because the European Union 
has 24 official languages plus Norwegian and Icelandic, which are also 
languages of the member states following cross-border patient health care and 
the Directive 2011/24/EU. It was not possible to include all of the languages of 
the member states, because of the complexity that would emerge in the 
perspectives. English was the most suitable language, it identified more studies 
and its visibility is significantly higher when compared to other languages.  
 
Study Records and Data 
When the selection of the three databases needed was done, the data was 
exported to excel format. The aim was to verify if there were duplicates and to 
identify them.  
 
Selection Process 
Two hundred and eighty records were screened through their titles and abstracts. 
Papers that did not match the inclusion criteria were excluded. Some of the 
articles were reviewed more than one time, to ensure that there was no doubt 
about the inclusion. After this, all the full texts downloaded studies were examined 
to collect the ones that included cross-border care, legislation (e.g.: Directive 24), 
barriers, and facilitators. A final list of 21 papers was gathered.  
 
Data Collection Process and Data Items 
The data extracted from reports was done independently. A meta-analysis was 
not performed, because European legislation, policy, and other related measures 
cannot be an estimation of a quantitative approach, since it is based on the 
interpretation of different perspectives. The aim is to evaluate those measures 
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through a systematic review, having in mind a broad framework of what literature 
is written about and what are the results found in the different studies. 
Through the analysis of the facilitators and barriers, there were identified 
independent variables or external factors that can influence cross-border 
healthcare. Legido- Quigley classified them into political factors, cultural and 
linguistic factors, and the nature of borders. For this study, all those factors can 
relate as an external variable, and also the financial factor is included. 
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Literature from 2009 to 2019 is reflected in 356 papers identified. Of these 
studies, 335 were excluded in the end, after the stages described in Figure 1. All 
the records (n= 280), except duplicates, were screened, through an analysis of 
titles and abstracts. 
In the next stage, 102 studies were reviewed for eligibility. At this point, it is 
pertinent to mention that 3 relevant papers were not accessible, even though a 
permission request was sent to the author. After the eligibility criteria were 
applied, a total of 21 studies were selected for the qualitative synthesis. 
The inclusion and exclusion criteria of the studies selected were based on a pre-
determined list of characteristics. In the first place, an association between 
European legislation and cross-border healthcare was established as inclusion 
criteria. E.g.: patients’ rights, European projects, regulations, and implementation 
of the mobility Directive 2011/24/EU. Secondly, the full-text assessment should 
include facilitators or barriers to cross border care. 
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Most of the studies (n= 21) were qualitative case-studies (6) and qualitative 
analysis (5). Also, there were analyzed three reviews and two expert interviews, 
an expert commentary, a key informant’s questionnaire, one chapter of a book, a 
project, and, finally, one survey. All of them can be found in Table 1 with a 
description. 
Studies included in the review were divided into two categories. Primary data was 
the content of 9 studies [(Bonanno et al., n.d.)(Azzopardi-Muscat et al., 
2018)(Vasev, 2017)(Dimitrios et al., 2016)(Glinos & Baeten, 2015)(Exter et al., 
2015)(Panteli et al., 2015)(Legido-Quigley et al., 2014)(Rosenkötter et al., 2013)] 
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and 12 studies used secondary data [(Erdös et al., 2019)(Montserrat Moliner & 
Waligora, 2017)(Riedel, 2016)(Marschang & Bernardo, 2015)(Van der Molen & 
Commers, 2013)(Kierkegaard, 2013)(Huić et al., 2013)(Hatzopoulos & Hervey, 
2013)(Legido-Quigley et al., 2012)(Legido-Quigley et al., 2011)(Pattynama, 
2010)(Laugesen & Vargas-Bustamante, 2010)]. 
 
 
Table 1 Summary characteristics of included studies 
Study type Reference and 
year 
Legislation addressed 
Expert commentary (Bonanno et al., 
2019) 
Regulation on Health Technology 
Assessment 
Study about the 
European  Network for 
Health Technology 
Assessment 
(Erdös et al., 
2019) 
Regulation on Health Technology 
Assessment 
Structured 
questionnaire of key 
informants 
(Azzopardi-
Muscat et al., 
2018) 
Directive 2011/24/EU (effects of the 
directive on health systems in 7 Member 
States) 
Chapter of a book  (Montserrat 
Moliner & 
Waligora, 2017) 
European Union Policy in the Field of 
Rare Diseases (Commission 
Communication, Council 
Recommendation, Directive on Cross-
border healthcare, which originated 
European Reference Networks) 
2 Case- studies  (Vasev, 2017) Directive 2011/24/EU (transposition in 
two countries) 
Qualitative analysis (Riedel, 2016) Directive 2011/24/EU 
Project (Dimitrios, 2016) Directive 2011/24/EU  
(ePrescription and Patient Summary 
Services) 
Seven case- studies (Glinos & 
Baeten, 2015) 
Directive 2011/24/EU (cross-border 
collaboration) 
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Three case-studies  (Exter et al., 
2015) 
Directive 2011/24/EU (prior 
authorization, national contact points, e-
health, mutual recognition of 
prescriptions, co-operation on health 
technology assessment) 
Review of patient’s 
perspectives 
(Marschang & 
Bernardo, 2015)  
European initiatives to achieve  
An anonymous postal 
survey by the 
Techniker 
Krankenkasse (one of 
the largest sickness 
funds in Germany) 
(Panteli et al., 
2015) 
Barriers to the exchange of information 
across borders from the patient’s 
perspective 
12 semi-structured 
interviews with key 
actors 
(Legido-Quigley 
et al., 2014) 





EU- level policy outputs 
Qualitative case study 
and legal framework 
(Van der Molen 
& Commers, 
2013) 
Liability and data protection (influential 






E- Prescriptions/ eHealth interoperability 
Retrospective analysis 
through 4 case studies  
(Huić et al., 
2013) 
Directive 2011/24/EU: health technology 
assessment 
Qualitative analysis (Hatzopoulos & 
Hervey, 2013) 
EU’s Court and cross-border healthcare 
Analysis of conceptual 
data and case studies 
of European projects, 
Walt and Gilson’s 
model of policy 
analysis 
(Legido-Quigley 
et al., 2012) 
Arrangements to set up a framework that 
would facilitate cross- border mobility 
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Qualitative analysis (in 
conjunction with the 
European Observatory 
on Health Systems and 
Policies) 
(Legido-Quigley 
et al., 2011) 
Directive 2011/24/EU 
Qualitative analysis (Pattynama, 
2010) 
International teleradiology (legal 
challenges) 




Government policies and documents in 
the United States and Europe 
 
 
Results of Individual Studies and Synthesis Results 
In the first place, the results of the review will be presented. Secondly, an 
assessment of the conclusions will be made to understand their importance and 
if this is up to date information. For each study, a summary of the most important 
information is presented in the next two tables. Graphics are used to better 
understand and analyze the studies’ conclusions. 
A facilitator in the context of cross-border care is different from the “benefit” it may 
bring to patients, professionals, and policymakers. It addresses mechanisms 
from a legal and political point of view. On the other hand, “barrier” is a possible 
obstacle to cross-border care.  
Although, it was thought that the growing movement of citizens and supportive 
legislation would bring to the higher mobility of patients’ needs, that did not 
happen. (Riedel, 2016) For this motive, it is important to understand the reasons 
behind it. Why did the Directive not stimulate cross-border patients’ mobility within 
member states? 
The goal of this study is to help in the understanding of how to improve the 
existing status quo and what are the opportunities.  If health could be 
institutionalized in the European policy, it would lead to a more equalized, 
harmonized system, with quality standards available to all Member States. 
(Laugesen & Vargas-Bustamante, 2010) 
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Table 2 summarizes the barriers’ results found in each study included in the 
review, which is, analyzed, and described below. 
 







The proposal for joint assessments of HTA does not address 
adequately issues of different methodologies across Europe; 
Consensus over comparators and treatment approaches 
(Erdös et al., 
2019) 
Practical barriers: language use, reporting structure, and the 
differences in national processes and methodologies, including 
the timing and scope of the assessments, can contribute to 
redundant HTA products 
(Azzopardi-
Muscat et al., 
2018) 
Cultural, language, and financial barriers; 
The countries which did not implement ECJ rulings (Poland, 
Malta, and Finland) before the transposition of the Directive, 
had misfits compared to others which defined benefit packages 








The Principle of Subsidiarity; 
National transposition of the Directive 2011/24/EU, because of 
socio-economic differences between countries 
(Riedel, 
2016) 
Two years after the Directive there is no increase in the number 
of patient mobility. 
(Dimitrios, 
2016) 
NCP systems and the set-up of legal and administrative rules 
are not validated at political levels; 
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eHealth interoperability challenges in all the countries and a 
lack of resources and skills to bring innovation;  
Technical and legal issues for cross-border transactions; 
European cooperation, national alignment, compatibility and 
sustainability of infrastructures, secure exchange of data, 




Feasibility in terms of coordination of different public health 
systems, because of the difficult and dependable collaboration 
(Exter et al., 
2015) 
Patient’s rights issues: access to medical records, complaint 
mechanism procedures, the system of liability insurance, EU 
data protection legislation; 
National Contact Points: the absence of good web-based 
information services in multilingual format; 
Difficulty in creating a fully mature and interoperable e-health 
system (e.g.: due to problems of lack of information and 
services exchange, clarity in legal norms on data protection, 
reimbursement issues); 
E- prescription system is not widely used. Prescribed 
authentication of cross border prescriptions, as it is impossible 
to pharmacists identify the correct product from a specific and 
different country brand, and to know if the country does not 
prohibit generic substitutions as it happens in Belgium and UK 
for example; 
Disregard of a multidisciplinary approach in health technology 
assessment, such as cost-effectiveness analysis, only taking 
into account the economic factor (cost-benefit analysis); 
Difficulty to create common criteria for a common method of 
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(Panteli et al., 
2015) 
Issues related to the management of continuity of care (e.g.: 
multimorbidity), safety concerns (e.g.: transportation of 
microorganisms); 
Medicines prescribed abroad (scarcity or lack of guidelines, 
prescription of different medication or lack of access to the 
medication prescribed); 
Informational exchange and low communication. Difficulty in 
the provision of electronic medical records and differences in 
format and content of the existing ones. 
Additional work on informing patients about their rights, the 
existing requirements, and communication is needed 
(Legido-
Quigley et al., 
2014) 
Teleradiology: 
Absence of a legal framework; 
Clinical governance of hospital managers between countries; 
Data security/ protection; 
Trust and acceptability between countries 
(Rosenkötter 
et al., 2013) 
The detachment of health and social policy at the EU-level, loss 





Liability and dearth of applicable rules at the European level; 
Data protection in cross border care, in the exchange of 




New e-Prescription technologies can raise concerns about 
citizen’s trust. Datamining and the possibility of interception of 
confidential data in the online environment; 
“Legal and regulatory issues are among the most challenging 
aspects of eHealth: privacy, confidentiality, data protection, and 
liability challenges.”; 
Member- States interpretation on Data Protection Directive 
(Huić et al., 
2013) 
“Barriers like late identification of collaborative partners, 
nonacceptance of English language, and different methodology 
of assessment should be overcome.” 
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Competitiveness and member states’ resistance (e.g.: systems 
such as English NHS have already implemented reforms, 
contrary to other countries); 
Principle of subsidiarity 
(Legido-
Quigley et al., 
2012) 
Legal contracts may become difficult, when two countries are 
incompatible in negotiations procedures, because of 
organizational characteristics. Aspects that may impact are: 
“differences in tariff-setting; the existence of contractual 
practices; differences in payment mechanisms of providers; the 
existence of a gate-keeper system; whether the system 
reimburses expenses or provides benefits-in-kind; the 
presence of over- or under-supply of services; the role of 
commercial actors in the system; differences in the 
organization of after-care; and whether health care has been 
devolved to lower tiers.”; 
Differences in costs; 
Cultural and linguistic factors; 
Borders and their nature, if for example countries are divided 
by sea or mountains, but also people’s perception of affinities 
in terms of culture or language; 
Cross-border health policies on the political agenda and 
variations between countries, its formulation, implementation at 
regional or national levels 
(Legido-
Quigley et al., 
2011) 
The Principle of Subsidiarity and tension between the Council 
of Ministers and the European Parliament; 
Issues that were left out of the Directive and to cooperation 
among the Member e-health- health services and standards of 
quality, rare diseases; 
Confusion in the implementation of the Directive and 
administration of this process (e.g.: prior authorization, costs, 
reimbursement of the treatment)  
(Pattynama, 
2010) 
Teleradiology: conflicts because of different legal 
interpretations; 
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Preauthorization requirements are a barrier to free movement 







eHealth Interoperability, Compatibility Between Health Systems 
Challenges: Access to Medical Records, ePrescriptions 
For every facilitator, there is a barrier and vice- versa. The most highlighted 
barrier coincides with the biggest facilitator, as eHealth is an important instrument 
of cross-border collaboration and care. The challenges of eHealth are related to 
interoperability, feasibility, national alignment, and compatibility between different 
0 5 10 15
Issues on different Health Technology Assessment
methodologies across Europe
Member states' resistance to cooperate and
exchange information (cultural, linguistic and
social factors)
Economic barrier, reimbursements and costs
Legal barrier, countries' political agenda, which did
not implement European legislation
The Principle of Subsidiarity
Lack of information and scarce patient mobility
eHealth interoperability, compatibility between
health systems challenges: access to medical
records, ePrescriptions
Data protection legislation and liability
Number of studies
Influential barriers identified through the 
review
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health systems. These are linked to the exchange and access to medical records 
information, complaint mechanism procedures, and ePrescriptions. 
It is a difficult collaboration, because of the dependable collaboration of every 
Member State. It is a complex process and informational exchange is difficult 
when there is low communication between MS. (Dimitrios, 2016)(Glinos & 
Baeten, 2015)(Exter et al., 2015) (Panteli et al., 2015)(Legido-Quigley et al., 
2014) 
The E-prescription system is not widely used and it becomes difficult to 
authenticate cross-border prescriptions. There is a lack of guidelines for the 
medicines prescribed abroad that sometimes can lead to difficult or impossible 
access to them. It is impossible to pharmacists to identify the correct product from 
a specific and different country brand, and to know if the country does not prohibit 
generic substitutions as it happens in Belgium and UK, for example. (Exter et al., 
2015)(Panteli et al., 2015) 
 
Member States' Resistance to Cooperate and Exchange Information  
In the second place, there is Member States’ resistance to cooperate because of 
cultural, linguistic, and social factors, a lack of trust and acceptability between 
countries. Although in some cases, the language factor, the proximity between 
cultures were facilitators for cross-border care, for the authors it is, most of all, a 
barrier.  
It seems that the lack of web-based information in a multilingual format, even with 
the existence of National Contact Points, it is still a barrier. (Azzopardi-Muscat et 
al., 2018)(Exter et al., 2015)(Legido-Quigley et al., 2014)(Hatzopoulos & Hervey, 
2013)(Huić et al., 2013)(Legido-Quigley et al., 2012) 
The Member’s states resistance exists also due to the economic factor:  
 
“The Polish and Maltese authorities also feared that long domestic waiting times 
could provide another motivation to seek care abroad. Furthermore, the 
authorities in Estonia and Poland, both countries with relatively low spending and 
pricing levels feared that the directive would encourage patients to seek 
expensive care abroad.”(Azzopardi-Muscat et al., 2018) 
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Legal Barrier and Countries' Political Agenda, Which Did Not Implement 
European Legislation 
Another misfit or challenge is the legal barrier, countries' political agenda, which 
did not implement European legislation or do not want to promptly implement. 
There is also the problem of confusion in the implementation process that rise 
differences between countries in matters such as prior authorization, costs, 
reimbursement, and treatment.  
Countries are detached from common or holistic health and social policy at EU-
level. The ones which did not implement ECJ rulings before the transposition of 
the directive had misfits compared to others which defined benefit packages and 
reimbursement procedures. The first had more work to adapt to new rules. In 
some countries, legal, administrative rules, and the NCP systems are not 
validated at political levels. E.g.: the biggest challenge to providing teleradiology 
services is the legal barrier. (Azzopardi-Muscat et al., 2018)(Dimitrios, 2016) 
(Legido-Quigley et al., 2014)(Rosenkötter et al., 2013)(van der Molen & 
Commers, 2013)(Legido-Quigley et al., 2012) (Legido-Quigley et al., 
2011)(Pattynama, 2010)(Laugesen & Vargas-Bustamante, 2010) 
A different kind of legal barrier is the difference in legal contracts that exist 
between countries, because of organizational characteristics. Those are: 
“differences in tariff-setting; the existence of contractual practices; differences in 
payment mechanisms of providers; the existence of a gate-keeper system; 
whether the system reimburses expenses or provides benefits-in-kind; the 
presence of over- or under-supply of services; the role of commercial actors in 
the system; differences in the organization of after-care; and whether health care 
has been devolved to lower tiers.”(Legido-Quigley et al., 2012) 
 
Data Protection Legislation and Liability 
Patient rights issues emerge also because of data protection and exchange of 
data, the system of liability insurance, EU data protection legislation, and the lack 
of clarity associated with legal norms. Challenging aspects of these legal and 
regulatory issues are mostly privacy and confidentiality. Although the Directive is 
an important instrument in this field, it did not resolve problems of the exchange 
of information and transparency between countries. (Dimitrios, 2016)(Exter et al., 
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2015)(Legido-Quigley et al., 2014)(van der Molen & Commers, 
2013)(Kierkegaard, 2013)  
The threat is, for example, the possibility of datamining practices, the interception 
of confidential data in the online environment. Although the information shared is 
anonymized, the patient can be de-identified through a profile that contains his 
habits, medications, pharmacies visited, and dates. (Kierkegaard, 2013) 
 
Economic Barrier, Reimbursements, and Costs 
Economic barrier, reimbursements, and costs are obstacles for some Member 
States, as sending patients to receive care abroad imply outflow of public funding 
that can threaten the sustainability of home health systems. This was one of the 
reasons that negatively affected the transposition of the patient’s rights directive, 
because of the existence of socio-economic differences between countries. 
Besides costs associated with reimbursement, there is also a lack of resources 
and skills to bring innovation, which is much needed in this context. (Azzopardi-
Muscat et al., 2018)(Vasev, 2017)(Dimitrios, 2016)(Exter et al., 2015)(Legido-
Quigley et al., 2012) 
 
Issues on Different Health Technology Assessment Methodologies across 
Europe 
Issues on different Health Technology Assessment methodologies across 
Europe appear and are intrinsic to HTA (e.g.: core model of EUnetHTA). It is 
difficult to get a consensus over comparators, common criteria, and treatment 
approaches. (Bonanno et al., n.d.) (Exter et al., 2015) There is disregard of a 
multidisciplinary approach in health technology assessment, such as cost-
effectiveness analysis, only taking into account the economic factor (cost-benefit 
analysis), which may put in risk the usefulness of the assessment. (Exter et al., 
2015)(Huić et al., 2013) 
 
“EUnetHTA identified that the process of application for reimbursement are 
started at different times in different Member States, with different criteria for the 
level of evidence requires by different Member States, thereby making further 
integration challenging.”(Bonanno et al., n.d.) 
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“Practical barriers such as language use, reporting structure, and the differences 
in national processes and methodologies, including the timing and scope of the 
assessments, can contribute to redundant HTA products.“(Erdös et al., 2019) 
 
The Principle of Subsidiarity 
The Principle of Subsidiarity and tensions between the Council of Ministers and 
the European Parliament led to difficulties of collaboration in the field of cross 
border care legislation and its further development. (Vasev, 2017)(Hatzopoulos 
& Hervey, 2013)(Legido-Quigley et al., 2011) 
 
Lack of Information and Scarce Patient Mobility 
Lack of information about their rights and scarce patient mobility requires more 
communication on cross border care. (Riedel, 2016)(Panteli et al., 2015) 
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European legislation on cross-border care is closely associated with its policies 
and, consecutively to related programs and mechanisms. Although there were 
identified several facilitators, not all of them influence the same, nor have the 
same nature. Table 3 summarizes the facilitators’ results found in each study 
included in the review, which are, analyzed, and described below. 
 




Facilitators or success factors 
(Bonanno et 
al., 2019) 
Collaboration on HTA: 
Joint standardized methodologies and tools through 
European Network for Health Technology Assessment 
(EUnetHTA) and other EU projects on the Health Technology 
Assessment (e.g.: MedTecHTA and INTEGRATE-HTA), 
medicinal products and devices, working with complex health 
technologies and new methods for assessment; 
European Commission published a Proposal for joint 
assessments of HTA incorporating Relative Effectiveness 
Assessments (REAs) to address different concerns 
(Erdös et al., 
2019) 
EUnetHTA was founded to support efficient production and 
use of health technology assessments (HTAs) by reducing 
redundancies. It laid a basis for cooperation and could bring 
quality, harmonize methodologies, transparency, and 
consistency contributing to economies of scale and health 
systems. 
Tools, methods, and processes used in the EUnetHTA formed 
a basis among over 80 European agencies:  
The POP database: shares knowledge, reduces duplications, 
and allows EUnetHTA partners to cooperate and share 
information about ongoing or planned projects; 
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The Core Model: a standardized reporting structure/ 
methodological framework for HTA; 
Methodological guidelines and procedure manuals for relative 
effectiveness assessment (REA) and other procedures 
(Azzopardi-
Muscat et al., 
2018) 
Directive 2011/24/EU- “European patients may benefit from a 
more explicit and thus transparent description of benefits 
packages where this was hitherto not the case. This increases 
access to the comparability of benefits packages thereby 
equipping patient groups with information to advocate for the 
introduction of additional benefits, indirectly setting normative 
benchmarks for health services. The introduction of 
professional indemnity insurance where this was previously 






European Community Framework Programs for Research 
and Technological Development (FP5, FP6, and FP7 
programs) have made substantial progress on rare diseases; 
Previous framework programs such as The Horizon 2020 for 
developing new therapies for rare diseases. Programs such 
as SC1-PM-03–2017: Diagnostic characterization of rare 
diseases; SC1-PM-08–2017; New therapies for rare 
diseases; the ERA-NET project E-RARE-3 for collaboration 
between EU countries in funding rare diseases, International 
Rare Diseases Research Consortium (IRDiRC)5; 
24 European Reference Networks on Rare Diseases will allow 
expertise to be shared between centers and lead to 
economies of scale. E.g.: confirm a diagnosis, medical 
procedures and operations, transplantations, and other 
invasive interventions; 
 
5 The European Commission together with international partners, initiated the International Rare 
Diseases Research Consortium (IRDiRC) in 2011, which aim is to deliver, by 2020, 200 new therapies for 
rare diseases and how to diagnose them. 
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“Commission Expert Group on Rare Diseases (CEGRD) has 
recently published recommendations to support the 
incorporation of rare diseases into social services and 
policies.”- Member states are called to take initiatives by the 
Council; 
Recommendation on action in the field of rare diseases, 
through national and regional planning. To build a supportive 
framework, the EU cofounded the EUROPLAN project and 






The cross-border healthcare mechanisms could lead to the 
harmonization of health care systems in Europe and 
contribute to a competitive European medical market; 
Influence on the sector of health through regulatory initiatives 




Evolving European eHealth through strategic policy such 




EU policies and tools to promote collaboration: legal 
framework through enhanced networking; financial 
instruments; border- region projects and necessary tools, 
commissions to evaluate good practices and research 
projects 
(Exter et al., 
2015) 
Directive 2011/24/EU:  
Prior authorization;  
National contact points; 
E-health: guidelines on standardization of patient’s summary 
records, electronic identification, and security of the 
exchange; 
Mutual recognition of prescriptions with guidelines supporting 
the interoperability of e-prescriptions; 
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Cooperation on health technology assessment: a 
multidisciplinary approach (medical, social, economic, ethical/ 
legal impact) and, finally, inform the health policymakers; 





National Contact Points; 
Advances in medical science and good medical practice; 
Use of new technologies and cooperation on strategic matters 




Quigley et al., 
2014) 
Teleradiology: 
Brings leadership commitment, and innovation; 
Adds value of service, making possible to offer specialist 
imaging to more people; 
Improve efficiency in the NHS (English case) 
(Rosenkötter 
et al., 2013) 
Existence of the Directorate general for health and consumers 
(DG SANCO) and the Public health program; 
EU agencies, that deal with public health topics: ECDC 
legislation on infectious disease control; EFSA control of 
health claims of food products; EMA coordination of the 
approval of efficacy, safety, and quality of drugs; EMCDDA; 
Health in all policies (HiAP) approach; 
Cooperation between EU, WHO, and OECD; 
Common tobacco legislation in Europe; 
Health Research Program; 
EU budget and related investments; 
Patients’ rights directive and cross- border cooperation, which 






Article 5: interoperability of patient’s medical records, which 
should be in line with the national measures on data 
protection, to facilitate the transfer of data; 
A SYSTEMATIC REVIEW ON THE EUROPEAN LEGISLATION AND POLICY OF CROSS- BORDER HEALTH 
CARE: BARRIERS AND FACILITATORS 
 
 57 
Article 14: e-Health network and inclusion of guidelines on the 
type of data that can be shared  
(Kierkegaard, 
2013) 
Interoperability of health systems improves quality and safety 
of care, because of the coordination, up to date patients’ 
information and e-prescriptions;  
Reducing prices for patients by unleashing the digital single 
market for healthcare and creating competition between 
pharmacies 
(Huić et al., 
2013) 
“(…) predefined project management, high degree of 
commitment to the project; adherence to timelines; high 
relevance of technology; a common understanding of the 
methods applied and advanced experience in HTA; 







Quigley et al., 
2012) 
Cross- border arrangements in general, as Busse et al. 
classified:  
Agreements between third-party payers/purchasers (in one 
country) and providers (in another), which aim is to set up 
arrangements when there are organizational hurdles such as 
waiting lists or when the purchasers and providers may 
behave in a market-like manner; 
Arrangements among providers, which aim to share 
infrastructures and personnel, sharing to avoid waste; 
Border area emergency care;  
Purchaser–purchaser collaboration with administrative 
arrangements; 
Institutional frameworks: legal mechanism of the social 
security system, that allows patients to receive treatment 
abroad and reimbursement for it. The EU established the 
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principles related to patient mobility for treatment in the 
Regulation 883/04; 
Directive 2011/24/EU on the informed choices and 
reimbursement for treatments abroad; 
The Government’s political backing of projects become 
relevant; 
Role of EU policies, projects, initiatives; 
Tariff setting and payment mechanism: Differences in costs; 
Funding opportunities for the arrangements, provided by the 
European Regional Development Fund and INTERREG 
programs; 
Quality assurance frameworks: development of shared 
protocols, controls before arrangements, transfer of patient 
files, and development of common medical documentation; 
Cultural and linguistic factors: structures may be built to 
promote cultural and social links between two regions 
(Legido-
Quigley et al., 
2011) 
Directive 2011/24/EU establishes: 
National Contact Points; 
Mutual recognition of prescriptions; 
System of European Reference Networks;  
Cooperation on e-health; 




The Directive 2011/24/EU; 





The exit of patients authorized by the Government can benefit 
the state and its payers “by addressing problems in a 
domestic health care system, such as capacity”, costs (e.g.: 
waiting lists, expensive facilities or treatment, efficiency- 
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The Collaboration of the Member States and eHealth, a Single Market for 
Healthcare, ePrescriptions, Medical Trials, and Data Protection 
The most influential mechanism for cross-border care is the eHealth as a single 
market, its interoperability, arrangements, and networking as defined by Directive 
24 (Article 14). E-health promotes collaboration on common safety and quality 
standards in all health systems. 
eHealth has evolving strategies related to ePrescription and Patient Summary 
(eP/ PS) services. Medical records require specific guidelines on the type of data 
that can be shared between healthcare professionals (transferability of data). 
This data must be in line with the Government’s policies and measures on data 
protection, to facilitate the transfer of data. This can bring a clearer and up to date 
patient’s information and, also, understandable prescriptions through 
ePrescription between pharmacies. (Dimitrios, 2016) (Van der Molen & 
Commers, 2013)(Kierkegaard, 2013) 
The European Commission is creating guidelines on “standardization of patients 
summary records to be exchanged across borders”, also taking measures for 
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across borders. The cross-border healthcare mechanisms could lead to the 
harmonization of health care systems in Europe and contribute to a competitive 
European medical market with regulatory initiatives and common standards. E.g.: 
medical trials, data protection, and pharmaceuticals  (Azzopardi-Muscat et al., 
2018)(Riedel, 2016)(Dimitrios, 2016)(Exter et al., 2015)(Marschang & Bernardo, 
2015)(van der Molen & Commers, 2013)(Kierkegaard, 2013) (Legido-Quigley et 
al., 2012)  
Electronic prescribing is suggested to solve the problem of incomplete 
prescriptions and decrease the number of adverse effects due to errors in hand-
written prescriptions. It will also decrease the number of errors, adverse drug 
events, double medication, contraindications, and dosage when compared to 
handwritten prescribing. Except for some countries, such as the Nordic countries, 
“a nation-wide e-prescription system” is not widely used in the EU. For example, 
in the Netherlands, e-prescribing is considered an indispensable element in the 
computerized information system. (Exter et al., 2015) 
 
“With e-Prescription, doctors can monitor the history of the patient’s medicine 
uses. It also enables the patient to obtain the medicine anywhere, avoiding the 
long waiting time.” (Kierkegaard, 2013) 
 
European Public Health Programme, Funded Projects, and Research  
The European Public Health Programme is important to annually establish 
border- region projects, joint actions, and necessary tools to the Member States, 
clarifying European policy on this field (e.g.: Health in all policies approach). The 
funding opportunities for the arrangements can be provided by European 
programs, such as Horizon 2020 or the European Regional Development Fund 
and INTERREG programs, for example. There are also projects related to 
research and technological development, which have made progress on rare 
diseases (FP5, FP6, and FP7 programs, ERA-NET project). (Montserrat Moliner 
& Waligora, 2017) (Glinos & Baeten, 2015)(Rosenkötter et al., 2013)(Legido-
Quigley et al., 2012) 
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Tools of Health Technology Assessment 
The European Network for Health Technology Assessment (EUnetHTA) is a tool 
of the HTA collaboration, which aim is to create a network of public national HTA 
agencies that could enable the exchange of information between Member States 
research institutes and health ministries. Since 2006, there were created different 
facilitators through this network: a Planned and Ongoing Projects (POP) 
Database and Evidence database on new technologies (EVIDENT), the 
EUnetHTA website, guidelines about project management, and a procedure 
manual for rapid relative effectiveness assessment (REA) and a standardized 
reporting structure: the CoreModel (with 9 domains of evaluation on health 
problems, the technology used, legal and social aspects, etc).  
This kind of assessment is a facilitator “per se” because it is supported on a 
multidisciplinary approach, based on legal, policy, or economic arguments and 
tends to be more transparent, accountable and examples of good governance. 
The CoreModel can help in the decision-making process of health policies. 
(Erdös et al., 2019)(Exter et al., 2015) 
Collaboration on HTA can reduce duplication, build capacity, improve the quality 
and efficiency of the assessment. (Bonanno et al., 2019)(Erdös et al., 2019)(Exter 
et al., 2015)(Huić et al., 2013) 
 
"There will be increased HTA collaboration across Europe over the next five years 
whether this is voluntary or governed by regulations. European countries will 
benefit in different ways from increased collaboration. Some will benefit more 
substantially than others addressing key issues such as availability of resources 
and personnel to fully undertake HTA evaluations. Methodologies will also 
improve as a result of collaborations, and there will be increased funding for joint 
research projects.”(Bonanno et al., 2019) 
 
National Contact Points 
The Directive 2011/24/EU is the most important legal facilitator of cross-border 
collaboration because it clarifies several facilitators and advocates safety, quality, 
and information for patients. The NCP’s aim is the dissemination of information 
about care standards, to empower patient’s informed choices, facilitate 
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professionals' and policymakers' work. (Marschang & Bernardo, 2015)(Legido-
Quigley et al., 2011)  
 
European Reference Networks and Council Recommendation 
Other facilitators are the 24 European Reference Networks and the Council’ s 
Recommendation on the field of Rare Diseases, which allow expertise to be 
shared between centers, the development of new care models, eHealth tools and 
solutions. They may lead to economies of scale if there will be an improvement 
in research through clinical studies and the consequent development of 
pharmaceuticals.  
This knowledge can have a positive outcome and efficient use of costs, especially 
for the Member States Health Systems and patients suffering from rare diseases. 
E.g.: confirm a diagnosis, medical procedures and operations, transplantations, 
and other invasive interventions. (Montserrat Moliner & Waligora, 
2017)(Azzopardi-Muscat et al., 2018)(Riedel, 2016) 
“Commission Expert Group on Rare Diseases (CEGRD) has recently published 
recommendations to support the incorporation of rare diseases into social 
services and policies.”- Member states are called to take initiatives by the Council 
Recommendation on the action in the field of rare diseases, through national and 
regional planning. To build a supportive framework, the EU cofounded the 
EUROPLAN project and EUCERD Joint Action. (Montserrat Moliner & Waligora, 
2017) 
 
Cultural, Linguistic and Social Factors 
At last, cultural, linguistic, and social factors is an external factor to consider. 
Habits, traditions, language, expectations, and familiarity with the country and 
health care system can either hinder or facilitate cross-border health care. 
(Legido-Quigley et al., 2011) 
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A SWOT analysis was performed to identify strengths, weaknesses, 
opportunities, and threats and to help draw more objective conclusions. For this 
purpose, all barriers and facilitators identified in the systematic review were 
distributed, as well as other significant observations were considered. It was 
observed that the facilitators were distributed between strengths and 
opportunities, depending on whether they were controlled or not, and barriers 
became weaknesses and threats.  
Strengths and weaknesses show the facts described and studied in the 
systematic review and opportunities and threats help in the understanding of 
future possibilities, also identified through the studies considered. This analysis 
aims to contribute to research, policymaking, and decisions in strategic planning.  
Here, follows the definition of the SWOT analysis made for this study. Strengths 
and weaknesses are considered to be both originated internally, while 
opportunities and threats are external factors. The first pair can be controlled, 
although strengths are positive and weaknesses are negative. Strengths are a 
list of capabilities and resources which support competitive advantage, for 
example, an innovative service, cultural affinity, a very good reputation, and 
expertise and other assets that add value.  
On the other hand, weaknesses are fields that need improvements or, 
sometimes, is the absence or the reverse of strength, for example, experiences 
of a bad reputation, gaps in services, or unfunctional technology. Opportunities 
and threats cannot be controlled and the first are helpful and the second are 
harmful. Opportunities reflect an addition to new, for example, new technology or 
changes in the population’s characteristics. Threats are anything that stands in 
the way of your success and may have costs, like a new competition, changes in 
reimbursement, or legal and economic challenges. 
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Facilitators, after analyzed, were divided into strengths and opportunities. Legal 
instruments in general and the Directive 2011/24/EU in particular, make cross-
border healthcare possible and clarifies patient’s rights. The Directive 
2011/24/EU defines all procedures related to cross- border healthcare, such as 
prior authorization, reimbursement, National Contact Points, e-health,  mutual 
recognition of prescriptions, cooperation on health technology assessment 
through the multidisciplinary approach, and inform health policymakers. (Exter et 
al., 2015)(Marschang & Bernardo, 2015)(van der Molen & Commers, 2013) 
(Legido-Quigley et al., 2012)(Legido-Quigley et al., 2011) 
Regulation 883/04 is a helping legal mechanism of the social security system, 
that allows patients to receive treatment abroad and reimbursement for it. 
(Legido-Quigley et al., 2012) This instrument is more favorably used for planned 
and unplanned care. While the Directive only covers the cost equivalent to the 
STRENGTHS
Legal instruments: Directive 2011/24/EU; 
Regulation 883/04 bi-lateral and multi-lateral 
parallel procedures 
EU- wide voluntary eHealth Digital Service 
Infrastructure (eHDSI) for ePrescriptions and 
Patient Summaries;
European Public Health Programme, funded 
projects and research;




eHealth interoperability related to 
compatibility between health systems;
Data protection liability;
Different HTA methodologies across Europe
OPORTUNITIES
eHealth as a single market for healthcare, 
harmonization of health care systems in 
Europe and competitive European medical 
market;
Contain Member States' costs and improve 
capacity;
Cultural, linguistic and social factors
THREATS
Member States resistance to cooperate and 
exchange information;
Legal barriers and countries' political 
agenda, protectivism and nationalism 
SWOT
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treatment in the home country, the Regulation covers full costs and does not 
require an upfront reimbursement claim. (Parliament, 2019)  
However, the Directive and Regulation are not the only ways by which care is 
provided outside of home countries. “Several Member States have adopted bi-
lateral and multi-lateral parallel procedures to address the needs of care in their 
countries.”(Wilson et al., 2018)(Van der Molen & Commers, 2013) 
There are funding opportunities for the cross- border arrangements, namely from 
European Regional Development Fund and INTERREG programs, Cross- border 
arrangements can be different, agreements between third-party 
payers/purchasers (in one country) and providers (in another), which can solve 
organizational hurdles such as waiting lists. There can also be arrangements 
among providers, which aim is to share infrastructures and personnel, avoiding 
waste or arrangements of border area emergency care, and, finally purchaser–
purchaser collaboration through administrative arrangements. (Legido-Quigley et 
al., 2012) 
The interoperability of health systems is a quality assurance framework, because 
it improves the quality and safety of care, keeping patients’ information up to date 
and cooperating towards better standards. (Legido-Quigley et al., 2012) This 
strength can be used in the patient’s favor,  reducing treatment prices, and 
leading to a digital single market for care. (Kierkegaard, 2013) Patients’ rights 
directive and cross- border cooperation gives legal certainty to policymakers. 
(Rosenkötter et al., 2013) 
The implementation of the EU- wide eHealth Infrastructure is in the working 
process and there are already some exchanges of information between 
countries. Only a few countries can send and receive ePrescriptions and patient’s 
data. The first exchanges took place between Estonia and Finland, but there are 
also exchanges between Croatia, Estonia, Finland, Czech Republic, Malta, 
Luxembourg, and Portugal.  These results are seen as victories, even if they do 
not reflect the European Commission’s expectations. (European Court of 
Auditors, 2018)  
Although data exchange is a strength, because of its latest developments, it is 
also an opportunity to cover all the Member States in the future. The Commission 
and the Member States are continuously building the EU- wide voluntary eHealth 
Digital Service Infrastructure (eHDSI) to help in the exchange of data on 
A SYSTEMATIC REVIEW ON THE EUROPEAN LEGISLATION AND POLICY OF CROSS- BORDER HEALTH 
CARE: BARRIERS AND FACILITATORS 
 
 66 
ePrescriptions and Patient Summaries, which are important strengths to cross- 
border care. (Dimitrios, 2016)  
The exchange of information has different benefits and some of them are 
described by Legido- Quigley and other authors, as teleradiology was proven to 
bring leadership and commitment with innovation, add the value of service, make 
expertise imaging possible to more people, and, finally, improve efficiency. 
(Legido-Quigley et al., 2014)  Teleradiology and telemedicine, in general, is seen 
as a solution to contain rising costs. (Pattynama, 2010) 
The European Public Health Programme, funded projects, and research are 
instruments that strengthen cross-border care. Cross- border healthcare is 
funded by the second (2008-2013) and third (2014-2020) Health Programmes, 
which totalize 64 million euros per year.  
The European Public Health Programme is important to annually establish 
border- region projects, joint actions, and necessary tools to the Member States, 
clarifying European policy in this field (e.g.: Health in all policies approach).  
(European Court of Auditors, 2018)  
From an international perspective, all the organizations such as OECD, EU 
agencies, WHO, and Directorate general for health and consumers work towards 
strengthening health. (Rosenkötter et al., 2013)  
The Commission also supports cross- border cooperation through studies and 
actions, such as Interreg, funded by European Structural and Investments Funds. 
(European Union, 2019) The funding opportunities for the arrangements can be 
provided by European programs, such as Horizon 2020 or the European 
Regional Development Fund and INTERREG programs, for example. (Glinos & 
Baeten, 2015)(Rosenkötter et al., 2013)(Legido-Quigley et al., 2012) 
The 24 European Reference Networks (ERN’s), specialized in rare diseases, 
cooperate with 952 highly specialized healthcare units from more than 300 
hospitals in the EU, EEA countries, and Norway. The Commission Expert Group 
on Rare Diseases (CEGRD) has recently published recommendations to support 
the incorporation of rare diseases into social services and policies. (Parliament, 
2019)(Montserrat Moliner & Waligora, 2017)  
ERNSs are considered to reduce the time of diagnosis, allow expertise to be 
shared, improve access to care for rare diseases, and offer platforms for the 
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development of guidelines and exchange of expertise or lead to economies of 
scale. (Montserrat Moliner & Waligora, 2017) 
ERNs are funded by the EU Health Program, which also helps in the development 
of IT tools and patient registries. In this context, a web-based application (Clinical 
Patient Management System or CPMS) with medical experts, share information 
on specific cases to get a high- quality diagnosis and treatment.  (European 
Union, 2019) 
There is an entire framework for rare diseases, which has brought progress, such 
as the European Community Framework Programs for Research and 
Technological Development (FP5, FP6, and FP7 programs), or previous 
programs such as the Horizon 2020. (Montserrat Moliner & Waligora, 2017) 
National Contact Points were considered a strength since they help in the 
exchange of information between countries and is generally used by the Member 
States.  They inform about whether patients seek care under the Directive or the 
Regulation, although there are some barriers to the clarification of that 
information. 
Although there are different methodologies of Health Technology Assessment 
and treatment approaches across Europe, Bonnano and other authors write 
about the fact that there is a need to collaborate and join standardized 
methodologies and tools, as it happens through the European Network for Health 
Technology Assessment (EUnetHTA) and other EU projects (e.g.: MedTecHTA 
and INTEGRATE-HTA), medicinal products and devices. (Bonanno et al., n.d.)  
As Erdös also states, EUnetHTA was founded to support efficient production and 
use of health technology assessments (HTAs) by reducing redundancies, 
bringing cooperation between the Member States, and harmonize transparency, 
quality, and consistency of methodologies. Eighty agencies work towards these 
objectives, forming the POP database to share the information. The instrument 
used to make the assessments is the framework of the Core Model, 




Interoperability between the Member States and its feasibility is complex, 
because of the different public health systems and dependable collaboration. 
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(Glinos & Baeten, 2015) There is more work to do towards solving issues to 
access medical records, complaint mechanism procedures, a system of liability 
insurance, and EU data protection legislation.  (van der Molen & Commers, 
2013)(Kierkegaard, 2013)  
E- prescription system is not, yet, widely used, which leads to problems of 
authentication of cross-border prescriptions and misfits in the correct brand of the 
products.  In some cases, medicines prescribed abroad lack guidelines, and at 
other times they are not available in those countries. (Exter et al., 2015)(Panteli 
et al., 2015)  
Patient summaries’ information is difficult to exchange between countries, 
because of the different formats, dissimilar content and there is general low 
communication. Issues of management and continuity of care, in cases like multi 
morbidity, for example, show a gap in cross border care. (Panteli et al., 2015)  
There is a lack of clarity in what concerns legal norms and data protection 
legislation, although it exists. Rosenkötter advocate that there is a detachment of 
health and social policy at the EU-level, which leads to a loss of collaboration 
between the Member States. (Rosenkötter et al., 2013)(Legido-Quigley et al., 
2014) (van der Molen & Commers, 2013)  
Clarity in data protection legislation is needed, because there are threats in the 
online environment, such as data mining and the possibility of interception of 
confidential data. (Kierkegaard, 2013)  
Different HTA methodologies across Europe lead to complications in address 
joint assessment and achieve consensus over comparators and treatment 
approaches. (Bonanno et al., 2019) Another weakness is that there are 
disregards of the multidisciplinary approach in HTA, such as cost-effectiveness 
analysis, only taking into account the economic factor (cost-benefit analysis). It is 
difficult to create common criteria for a common method of assessment such as 
the core model of EUnetHTA. (Exter et al., 2015) 
Practical barriers such as language use, reporting structure, and the differences 
in national processes and methodologies, including the timing and scope of the 
assessments, can contribute to redundant HTA products. (Erdös et al., 2019) 
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“Barriers like late identification of collaborative partners, nonacceptance of 
English language and different methodology of assessment should be 
overcome.”(Huić et al., 2013) 
 
Opportunities 
EU- wide voluntary eHealth Digital Service Infrastructure (eHDSI) for 
ePrescriptions and Patient Summaries is a strength and an opportunity, which 
seeks to connect European eHealth systems through National Contact Points for 
eHealth. It positively affects cross-border care internally and externally.  
Internally, because citizens can have access and exchange their health data 
across borders through eHDSI. (European Union, 2019) The first exchange took 
place between Estonia and Finland in January 2019, but 22 Member States are 
expected to exchange such information by 2021. By now more countries manage 
to do this exchange of information. (Gabriel, 2019)  
Riedel states that cross-border healthcare mechanisms could lead to the 
harmonization of health care systems in Europe and contribute to a competitive 
European medical market with regulatory common standards, for example, 
medical trials, data protection, and pharmaceuticals. (Riedel, 2016) Kierkegaard 
analyzes cross- border care efficiency through interoperability as an opportunity 
to reduce prices for patients in healthcare and creating competition between 
pharmacies. (Kierkegaard, 2013) 
Erdös and authors state that EUnetHTA was founded to support efficient 
production and use of health technology assessments (HTAs) by reducing 
redundancies. It laid a basis for cooperation and could bring quality, harmonize 
methodologies, transparency, and consistency contributing to economies of 
scale and health systems. (Erdös et al., 2019)(Bonanno et al., n.d.) 
The exit of patients for treatments abroad, authorized by the Government, can 
benefit the state and its payers “by addressing problems in a domestic health 
care system, such as capacity”, costs (e.g.: waiting lists, expensive facilities or 
treatment, efficiency- especially in small countries). (Erdös et al., 
2019)(Laugesen & Vargas-Bustamante, 2010)  
On the other hand, cultural, linguistic, and social factors may build structures to 
promote links between regions, which can lead to the economic growth of those 
regions. (Legido-Quigley et al., 2012) 
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Member States' competitiveness and resistance to cooperate and exchange 
information is a threat, because of the lack of feasibility in terms of coordination 
of different public health systems and the absence of effective communication. 
(Dimitrios, 2016)(Glinos & Baeten, 2015) Legal contracts may become difficult, 
when two countries are incompatible in negotiations procedures, because of 
organizational characteristics.  
Different scenarios may impact negotiations, namely “differences in tariff-setting; 
the existence of contractual practices; differences in payment mechanisms of 
providers; the existence of a gate-keeper system; whether the system reimburses 
expenses or provides benefits-in-kind; the presence of over- or under-supply of 
services; the role of commercial actors in the system; differences in the 
organization of after-care; and whether health care has been devolved to lower 
tiers.” (Legido-Quigley et al., 2012) 
The collaboration of Member States in legal matters and arrangements is crucial 
for the future success of cross-border care. (Azzopardi-Muscat et al., 2018) 
(Vasev, 2017) The Government’s political backing of projects is an important step 
to help cross border care in its progress. (Legido-Quigley et al., 2012) 
Legal barriers related to the countries' political agenda may, also, difficult the 
communication between the Member States and European Institutions. 
(Dimitrios, 2016) Different can be the determinants of this threat, some countries 
do not implement readily and correctly all the rulings, as it happened with the 
Directive and its definition of benefit packages and reimbursement procedures 
(cases of Poland, Malta, and Finland). (Azzopardi-Muscat et al., 2018)  
Vasev justifies the difficulties of the Directive’s transposition, advocating that this 
happens because of socio-economic differences between countries.  (Vasev, 
2017) In other cases, NCP systems and the set-up of legal and administrative 
rules are not validated at political levels. (Dimitrios, 2016) 
Protectionism and nationalism are ideologies that may be a threat to future 
cooperation of the Member States and further integration and work in cross 
border care. For example, the preauthorization requirements make free 
movement within the E.U. more complicated, because it involves bureaucracies 
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Discussion and Conclusions 
 
Summary of Evidence 
The review identified facilitators and barriers in the context of cross border 
collaboration and care. Summarizing the main findings, it becomes clear that, 
although it is complex to develop such a legal framework that would embody 
common standards and principles of cross- border care and interoperability, there 
is a possibility to build more with the existing instruments. The solution resides 
within the facilitators and internal factors barriers solving.  
Member States collaboration and external to the European Union legal 
framework factors could grow a positive approach to better cross- border care. 
HTA brings leadership and commitment to innovate, adding value to services, 
and improving the efficiency of health systems. (Exter et al., 2015)(Legido-
Quigley et al., 2014)(Van der Molen & Commers, 2013) 
The European funding and legal framework, especially empowered by Directive 
2011/24/EU lead the work on this front. This legal instrument gave certainty to 
policymakers that now can address the legal and financial aspects of their 
systems. E.g.: waiting lists, management of treatment of rare diseases, and 
underused facilities.  
The benefits for patients’ health are strong whenever a rare disease may be 
treated abroad, an efficient technology assessment is provided through a 
multidisciplinary approach or expertise of practices and knowledge is shared. 
Healthcare providers and professionals would have the access to knowledge and 
diversity of treatments that exist in Europe and also become familiar with 
legislation and quality standards. (Exter et al., 2015) (Legido-Quigley et al., 2011)  
Contrary to these assumptions, Riedel points to the failure of a European medical 
market with harmonized practices, defending that there is no increase in patient 
mobility and the Directive failed to accomplish its objectives. One of the reasons 
for this is that the European health systems have been organized around the 
principle of territoriality and European policies exceed the domestic rules 
(Principle of Subsidiarity). (Riedel, 2016)(Marschang & Bernardo, 2015) 
The EU is a public and supportive player in health, coordinating the MS actions, 
and helping financially, but it requires further developments. (Rosenkötter et al., 
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2013)(Glinos & Baeten, 2015) Besides all the European efforts, there is a lack of 
a legal transparent framework that could guarantee data security, trust, and 
clinical governance. (Legido-Quigley et al., 2014) 
The collaboration of governments is very important, although their legal and 
political agenda is not always favorable to incorporate European principles, as 
the review showed. Also, the economic factor is a barrier, because sending 
patients to receive care abroad implies the outflow of public funding that can 
threaten the sustainability of home health systems. (Vasev, 2017)(Exter et al., 
2015) (Legido-Quigley et al., 2011)  
When the financial sector may be threatened, innovation and know-how become 
less of a priority. If there is an argument that the country can build innovation and 
technology by itself, a collaborative perspective seems difficult to accomplish.  
 
Limitations  
Internal validity and limitations of this systematic review are associated with the 
qualitative interpretations of the studies reviewed by the author. Although a 
systematic review is usually associated with quantitative analysis, this was not 
done in this study, which chose a qualitative approach to analyze European tools 
and legislations.  
Secondly, a possible limitation is the fact that it was electronic research, without 
the exploration of libraries and some articles were not accessible to the author, 
even though access was required. 
The external validity and comparison with other similar studies can be divided 
into two categories. First, the barriers and facilitators identified through the 
European Institutions, which grant the validity of first-hand information, but may 
have a European policy perspective, and, second the independent studies 
analyzed through the review. 
There is a clear association between the results found in this study and the ones 
found by other studies, although the ones pointed by the author are more 
detailed. Mostly, the results found coincide with the ones found through other 
studies.  
Through this Systematic Review is possible to analyze the most influential 
facilitators and barriers. The Parliament of the European Union, European 
Commission- Health and Food Safety, as well as independent researchers as 
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Azzopardi and Hatzopoulos and Hervey highlighted political and governmental 
barriers in the Directive’s transposition. This result can relate to one of the most 
influential barriers found thorough the Systematic Review.  
Other barriers identified through the European Commission and European Court 
of Auditors are associated with eHealth, also one of the most influential barriers 
pointed by the report. The low number of patients traveling for care is justified by 
difficulties in national systems of reimbursement, prior authorizations, charging of 
incoming patients, and other administrative requirements.  
Again, the political and governmental barrier is shown by the midterm evaluation 
for the Programme’s eHealth action plan 2012-2020 concerning its adoption, 
complexity, governance, local conditions, and stakeholder engagement.  
A barrier not identified through the Systematic Review, but pointed out as 
important by the European Parliament is the challenge related to the continuity of 
care after the cross- border treatment. This outcome can be related to the 
exchange of information between health professionals and organizational and 




It was observed that, although the instruments for cross-border care are 
operable, there is a gap in the use of these services. There is work to be done in 
the practical front of cross border care. The flow of patients is low and barriers 
have to be overcome, otherwise, a potential European medical market cannot be 
developed. Authors write about the lack of clarity of the Directive, which persists 
in matters such as data protection and its liability.  
Implications of the results found will bring more systematized information about 
facilitators and barriers of cross border care in future research. All bibliography 
studied showed that there is a lack of clarity of all the treatment process, policy, 
and legislative framework, the best way of treatment from a patient’s perspective 
and that patients do not know about their health rights brought by the Directive 
and Regulation.  
There is a need to simplify the European framework of cross border care from a 
bottom-up perspective, to develop a stronger local structure of this kind of 
cooperation. As this is a dynamic and always progressing, mutable area, for 
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example in policies adopted when a Pandemic as Coronavirus arrives and the 
way it influences the Member States, there is a focus that needs to be addressed 
in the research of Public Health and a necessity to bring policy solutions. The 
second is not easy to address, as politics depends on the Government’s agenda, 
which does not always have a focus on cross-border care.   
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